login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

New European guidelines set to benefit heart failure patients in the UK


Thursday, 07 Jun 2012 11:13

The new guidelines state that the combination of “an ACE inhibitor [or angiotensin receptor blocker (ARB)], a beta-blocker, and an MRA, are fundamentally important in modifying the course of systolic heart failure and should at least be considered in every patient”.

 

This update provides welcome guidance to UK clinicians as it builds upon existing NICE guidance developed before the EMPHASIS-HF trial results were published.

 

Results of the EMPHASIS-HF trial showed that eplerenone (Inspra, Pfizer) reduces the risk of cardiovascular death or heart failure hospitalisation by more than a third compared to placebo in heart failure patients already receiving current standard therapy (RRR = 37%, p<0.001; ARR = 7.6%, p<0.001). These results were achieved against a quality of background therapy seldom seen in day to day clinical practice – 94% of patients in the eplerenone arm were also receiving an ACE inhibitor and over 86% were receiving a beta-blocker – highlighting the additive benefit of MRAs over standard therapy.

 

“The inclusion of eplerenone and mineralocorticoid receptor antagonists in the latest ESC guidelines is a significant step in making these life saving and cost effective treatments available to patients that need them,” said Martin Cowie, professor of Cardiology at Imperial College and consultant cardiologist at the Royal Brompton Hospital, London, UK. “Eplerenone should be offered to all eligible patients who continue to exhibit symptoms as it has been shown not only to save lives but, importantly, help keep patients out of hospital.”

 

Eplerenone has also been shown to reduce the likelihood of patients being admitted to hospital (due to heart failure) by over 40% (RRR 42%, p<0.001; ARR 6.8%, p<0.001). Hospitalisation due to HF is commonplace and every heart failure emergency admission costs at least £2,400.

 

Health economic analysis of eplerenone in patients with chronic heart failure (NYHA class II) have shown that eplerenone as an add-on to standard optimal therapy is highly cost-effective compared to standard therapy alone, with an incremental cost per Quality Adjusted Life Year (QALY) gained of £3,534, well below the lower £20,000 threshold typically viewed by NICE as representing good value for money.

 

Eplerenone has recently been approved in the UK to reduce the risk of cardiovascular mortality and morbidity in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (left ventricular ejection fraction ≤30%), in addition to standard optimal therapy. It is also indicated to treat patients with heart failure and left ventricular ejection fraction ≤ 40%, after recent myocardial infarction again, alongside standard therapy.




Add New Comment

Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

French hospital celebrates 30 years of implanting artificial hearts
Wednesday, 13 Apr 2016
La Pitié-Salpêtrière Hospital (Paris, France), the world’s leading artificial heart centre, is celebrating the 30th anniversary of the first Total Artificial Heart implantation. The centre has now ... French hospital celebrates 30 years of implanting artificial hearts

Tuesday, 05 Apr 2016
One-month, follow-up patient cohort data from the Revelution trial of Medtronic’s novel drug-filled stent indicate that device is associated with rapid vessel healing without inflammation, as ... Early data show good rapid healing for Medtronic’s investigational drug-filled stent

Features


Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy
Monday, 09 May 2016
According to Usman Baber, TWILIGHT is a unique and innovative study in that the experimental intervention is to withdraw rather than add to existing background pharmacotherapy. In this commentary, he ... Exploring the role of P2Y12 inhibitor monotherapy after dual antiplatelet therapy

The role of sutureless and rapid-deployment valves
Tuesday, 05 Apr 2016
Antonio Miceli explores the data for sutureless and rapid-deployment surgical valves for the management of patients with severe aortic stenosis. He also reviews the place of these new devices ... The role of sutureless and rapid-deployment valves

Profiles


Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions